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后遗症。3C 蛋白酶是 EV71 病毒复制过程中的一个重要蛋白酶，在 EV71 的成熟
过程和拮抗宿主细胞的先天性免疫反应中有着重要作用。因此，EV71 3C 蛋白酶








































The frequent outbreaks of hand, foot and mouth disease ( HFMD) that cause 
severe suffering, or even death, in large numbers of infants and children. Up to date , 
however, no vaccines or antiviral therapies are available for the prevention and 
treatment. Enterovirus 71 (EV71) is the major causative agent of HFMD and can 
spread its infections to the central nervous and other systems with severe 
consequences. EV71 3C protease is an important protease for virus replication, it 
plays important roles in the virus maturation and antagonism of the innate immune 
response of host. Therefore, EV71 3C protease is a very good drug targets for  
anit-EV71. 
AG7088 is a compound originally designed for Rhinovirus 3C protease. It has 
been confirmed that it can effectively inhibit EV71 activity, and we also have 
determined the complex structure of EV71 3C and AG7088. Because of the poor 
plasma stability and the low bioavailability in vivo, AG7088 cannot become the 
anti-EV71 drug. We use protein crystallography method to study the complex 
structures of EV71 3C and AG7088 with different length. We have analyzed the  
mechanism of the different length AG7088 binding to protein substrates pocket, and 
assessed the effect of the length of compound on the compound properties. The results 
found that the P3 part of compound significantly increased the ability of compound 
binding to proteinase; P4 part not only promote the binding ability, also greatly help 
the compound to across cell membrane. Meantime, we used the main chain of 
AG7088 as basic skeleton, introduced 2-pyridine in R3 group, and synthesized a 
series of 2-pyridine containing peptidomimetics. We have optimized P2 and P4 
groups based on structure-based drug design. Finally we get compounds 247 that not 
only has good antiviral activity, also has high stability of plasma. This research have 
laid a solid foundation for the improvement and development of anti-EV71 drug. 
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手足口病（Hand foot and mouth disease，HFMD），是一种高致病性传染病，
主要由肠道病毒 71 型（enterovirus 71，EV71）和科萨齐 A16 病毒（coxsackievirus 






发手足口病，造成 31 名儿童死亡[3]。1998 年，台湾爆发的手足口病导致约 150




示，2008 年总计 489,097 例手足口病病例，其中重症 1,125 例，126 人死亡；2009
年总计 1,155,525 例手足口病，其中包括 10,509 例重症，353 人死亡；2010 年 1
月 1 日至 11 月 30 日，超过 170 万人感染了手足口病，其中 905 人死亡。2010
年，手足口病成为中国感染人数最多的传染病，是卫生部重点监控的传染病之一。
2011 年共有手足口病 1,340,259 例，其中死亡人数 437 例；2012 年共有手足口病
1,520,274 例，死亡 431 人；2013 年共有手足口病 1,697,696 例，死亡 245 人；2014




























柯萨奇病毒以及肠道病毒 71 型等[8]，其中肠道病毒 71 型（EV71）和柯萨奇病毒
A16 型（Cox A16）是最为常见的病原体。其中，EV71 病毒会侵入中枢神经系
统，引起严重的并发症，容易造成后遗症，甚至死亡，给婴幼儿带来了极大的威








































1.2 肠道病毒 EV71 型（EV71）概述 
EV71 属于典型的小 RNA 病毒（Picornaviridae），根据 VP1 和 VP4 蛋白的序
列被分为 4 种基因型，即 A 型，B 型，C 型和 D 型[4]。在美国和澳大利亚，1969
年流行的 EV71 病毒为 A 型；20 世纪 70 年代流行的为 B1 型；80 年代为 B2 型；
90 年代则流行 C1 型，此时澳大利亚还伴随流行 B3 和 B4 型[10]。在过去的 30 年
中，导致手足口病大规模流行的 EV71 主要是属于 C 型。从 1986 年至 2008 年，
C1 型主要在中国、英国以及美国出现，而 C2 型主要出现在中国台湾地区，C3
型主要见于韩国。近些年来，在亚洲爆发的 EV71 多为 C4 型[11]。 
1.2.1 EV71 的基因组 
EV71 基因组是一单股正链RNA，由约7.4 kb核苷酸构成，只有一个开放阅
读框，可编码一约为250 kDa大小的多聚蛋白（polyprotein）[12]（图1-1）。在基因
组的5’端和3’端分别有约为745 nt的5’非编码区 (untranslated region，UTR) 和约






















图 1-1 EV71 基因组结构[15] 












白的切割，3D是依赖于RNA的RNA多聚酶（RNA dependent RNA polymerase），
负责病毒基因组的复制。 






















 图1-2 EV71的病毒结构[16] 







1.2.3 EV71 的生活周期 

















Degree papers are in the “Xiamen University Electronic Theses and 
Dissertations Database”.  
Fulltexts are available in the following ways: 
1. If your library is a CALIS member libraries, please log on 
http://etd.calis.edu.cn/ and submit requests online, or consult the interlibrary 
loan department in your library. 
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn 
for delivery details. 
厦
门
大
学
博
硕
士
论
文
摘
要
库
